Important pharmacy news and late-breaking industry information updated daily.
Even though 12 have been approved, what’s the reality for biosimilars in the U.S.?
A large clinical trial found that the drug icosapent ethyl (Vascepa—Amarin Pharms) dramatically reduced the rate of cardiovascular events in people with a history of heart disease or Type 2 diabetes, according to early results that were announced on Monday. The findings were particularly relevant for people with high triglycerides.
AstraZeneca's diabetes drug dapagliflozin (Farxiga) met a key goal in a major clinical study designed to show its heart-protecting benefits in a wide range of patients. The cardiovascular (CV) profile of medicines to treat diabetes is an important focus for doctors and patients.
Local pharmacies can still have a competitive edge, however
Researchers investigated the effect of post-discharge thromboprophylaxis in patients hospitalized for a medical illness but still at risk for venous thromboembolism upon release. The MARINER clinical trial randomized high-risk patients to a 45-day course of rivaroxaban or to placebo.
Agency also approves new REMS education Blueprint, changes in safety labeling
HHS this week awarded over $1 billion in opioid-specific grants. The awards support the agency's Five-Point Opioid Strategy, which was launched last year and enhanced this week.
FDA announced that it has approved the final Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS).
Honorees are Lisa Tonrey, Balls Food Stores, Federal Bureau of Prisons pharmacy programs
The Senate on Monday passed legislation enabling pharmacists to inform consumers when it is cheaper to buy a drug without insurance. The Patient Right to Know Act bans the use of gag clauses in insurance plans offered in the private market. The Senate earlier this month passed a similar bill barring these provisions in Medicare.